The variety of ecstasy/mdma users: Results from the national epidemiologic survey on alcohol and related conditions

American Journal on Addictions

Volumn 18, Issue 6, 2009, Pages 452-461

  Wu, Li Tzy ^a   Parrott, Andy C ^b   Ringwalt, Christopher L ^c   Yang, Chongming ^d   Blazer, Dan G ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c PACIFIC INSTITUTE FOR RESEARCH AND EVALUATION   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CANNABIS; COCAINE; OPIATE; SEDATIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; SUBSTANCE ABUSE; TOBACCO;

ADOLESCENT; ADULT; ALCOHOLISM; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HALLUCINOGENS; HEALTH SURVEYS; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SMOKING; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; UNITED STATES; YOUNG ADULT;

EID: 70449111706     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.3109/10550490903206049     Document Type: Article

References (55)

1. Parrott AC. Drug-related harm: a complex and difficult concept to scale. Hum Psychopharmacol. 2007;22:423-425.
2. MontoyaAG, Sorrentino R, Lukas SE, Price BH. Long-term neuropsychiatric consequences of 'ecstasy' (MDMA), a review. Harv Rev Psychiatry. 2002;10:212-220.
3. Cowan RL. Neuroimaging research in human MDMA users: a review. Psychopharmacology. 2007;189:539-556.
4. Reneman L, deWin MM, van den BrinkW, Booij J, den Heeten GJ. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol. 2006;20:164-175.
5. Gouzoulis-Mayfrank E, Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol. 2006;20:188-193.
6. Medina KL, Shear PK. Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use. Drug Alcohol Depend. 2007;87:303-311.
7. Parrott AC. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol. 2006;20:147-163.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., Text revision. Washington, DC: American Psychiatric Association; 2000.
9. Koesters SC, Rogers PD, Rajasingham CR.MDMA("ecstasy") and other "club drugs." The new epidemic. Pediatr Clin North Am. 2002;49:415-433.
10. Maxwell JC. Party drugs: properties, prevalence, patterns, and problems. Subst Use Misuse. 2005;40:1203-1240.
11. Patel MM, Wright DW, Ratcliff JJ, Miller MA. Shedding new light on the "safe" club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-210.
12. Substance Abuse and Mental Health Services Administration. Club drugs, 2001 update. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2002.
13. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE.Overall, illicit drug use byAmerican teens continues gradual decline in 2007. AnnArbor, MI: University of Michigan News Service [online]; 2007. Available at: www.monitoringthefuture.org. Accessed March 30, 2008.
14. Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2008.
15. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Various stimulant drugs show continuing gradual declines among teens in 2008, most illicit drugs hold steady. University of Michigan News Service: Ann Arbor,MI; 2008. http://www.monitoringthefuture.org/pressreleases/ 08drugpr.pdf. Accessed on March 23, 2009.
16. Carlson RG, Wang J, Falck RS, Siegal HA. Drug use practices among MDMA/ecstasy users in Ohio: a latent class analysis. Drug Alcohol Depend. 2005;79:167-179.
17. ParrottAC.Human psychopharmacology of ecstasy (MDMA),a reviewof 15 years of empirical research. Human Psychopharmacol. 2001;16:557-577.
18. Strote J, Lee JE, Wechsler H. Increasing MDMA use among college students: results of a national survey. J Adolesc Health. 2002;30:64-72. (Pubitemid 34037879)
19. Wu LT, SchlengerWE, Galvin DM. Concurrent use ofmethamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug Alcohol Depend. 2006;84:102-113.
20. Winstock AR, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend. 2001;64:9-17.
21. Muth́en B, Muth́en LK. Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes. Alcohol Clin Exp Res. 2000;24:882-889.
22. Wu LT, Blazer DG, Patkar AA, Stitzer ML, Wakim PG, Brooner RK. Heterogeneity of stimulant dependence: aNationalDrugAbuse Treatment Clinical Trials Network (CTN) study. Am J Addict. 2009;18:206-218.
23. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, and disability of personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2004;65:948-958.
24. Grant BF. The impact of a family history of alcoholism on the relationship between age at onset of alcohol use and DSM-IV alcohol dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. Alcohol Health Res World. 1998;22:144-147.
25. Hser YI, Anglin MD, Grella C, Longshore D, Prendergast ML. Drug treatment careers: a conceptual framework and existing research findings. J Subst Abuse Treat. 1997;14:543-558.
26. Keyes KM, Martins SS, Hasin DS. Past 12-month and lifetime comorbidity and polydrug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2008;97:139-149.
27. Wu LT, Ringwalt CL,Mannelli P, Patkar AA. Hallucinogen use disorders among adult users of MDMA and other hallucinogens. Am J Addict. 2008;17:354-363.
28. Grant BF, Dawson DA, Stinson FS, Chou PS, Kay W, Pickering R. The Alcohol Use Disorders and Associated Disabilities Interview Schedule- IV (AUDADIS IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. Drug Alcohol Depend. 2003;71:7-16.
29. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatr. 2004;61:807-816.
30. Wu LT, Howard MO, Pilowsky DJ. Substance use disorders among inhalant users: results from the National Epidemiologic Survey on alcohol and related conditions. Addict Behav. 2008;33:968-973.
31. Research Triangle Institute. SUDAAN user's manual, release 9.0. Research Triangle Park, NC: Research Triangle Institute; 2006.
32. Muth́en BO,Muth́en LK. Mplus: Statistical analysis with latent variables (version 4.2.1). Los Angeles, CA: Muth́en and Muth́en, Inc.; 2007.
33. Celeux G, Soromenho G. An entropy criterion for assessing the number of clusters in a mixture model. J Classif. 1996;13:195-212.
34. Nylund KL, Asparouhov T,Muth́en B. Deciding on the number of classes in latent class analysis and growth mixture modeling. A Monte Carlo simulation study. Struct Equ Model. 2007;14:535-569.
35. Boys A, Marsden J, Strang J. Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res. 2001;16:457-469.
36. Parrott AC. Chronic tolerance to recreational MDMA 3,4- methylenedioxymethamphetamine) or ecstasy. J Psychopharmacol. 2005;19:71-83.
37. Parrott AC, Morinan A, Moss M, Scholey A. Understanding drugs and behaviour. Chichester: Wiley; 2004.
38. Koob GF, Le Moal M. The neurobiology of addiction. Elsevier, MA: Academic Press; 2006.
39. Soar K, Turner JJ, Parrott AC. Psychiatric disorders in ecstasy (MDMA) users: a literature review focusing on personal predisposition and drug history. Hum Psychopharmacol. 2001;16:641-645.
40. Thomasius R, Petersen KU, Zapletalova P, Wartberg L, Zeichner D, Schmoldt A. Mental disorders in current and former heavy ecstasy (MDMA) users. Addiction. 2005;100:1310-1319.
41. Jessor R. New perspectives on adolescent risk behavior. In: Jessor R, ed. New perspectives on adolescent risk behavior. Cambridge, United Kingdom: Cambridge University Press; 1998: 1-10.
42. McGue M, Iacono WG. The association of early adolescent problem behavior with adult psychopathology. Am J Psychiatry. 2005;162:1118-1124.
43. Newcomb MD, Felix-Ortiz M. Multiple protective and risk factors for drug use and abuse: cross-sectional and prospective findings. J Pers Soc Psychol. 1992;63:280-296.
44. Rogers RD, Robbins TW. Investigating the neurocognitive deficits associated with chronic drugmisuse. Curr Opin Neurobiol. 2001;11:250-257.
45. Wilens TE, Biederman J, Bredin E, et al. A family study of the highrisk children of opioid- and alcohol-dependent parents. Am J Addict. 2002;11:41-51.
46. Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend. 1999;55:105-115.
47. Brick J. Handbook of the medical consequences of alcohol and drug abuse. New York: The Haworth Press; 2004.
48. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, Daumann J. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J Neural Transm. 2007;114:959-968.
49. Thomasius R, Zapletalova P, Petersen K, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol. 2006;20:211-225.
50. Hamida SB, Tracqui A, de Vasconcelos AP, et al. Ethanol increases the distribution of MDMA to the rat brain: possible implications in the ethanol-induced potentiation of the psychostimulant effects of MDMA. Int J Neuropsychopharmacol. 2008:1-11.
51. Izco M, Orio L, O'Shea E, Colado MI. Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity in rat brain. Psychopharmacology (Berl). 2007;189:459-470.
52. Klitzman RL, PopeHGJr,Hudson JI.MDMA("ecstasy") abuse and highrisk sexual behaviors among 169 gay and bisexual men. Am J Psychiatry. 2000;157:1162-1164.
53. Klitzman RL, Greenberg JD, Pollack LM, Dolezal C. MDMA("ecstasy") use, and its association with high risk behaviors, mental health, and other factors among gay/bisexualmen in NewYork City. Drug Alcohol Depend. 2002;66:115-125.
54. Parrott AC, Milani RM, Parmar R, Turner JJD. Recreational ecstasy/ MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology. 2001;159:77-82.
55. Wu LT, Parrott AC, Ringwalt CL, Patkar AA, Mannelli P, Blazer DG. The high prevalence of substance use disorders among recent MDMA users compared with other drug users: Implications for intervention. Addict Behav. 2009;34:654-661.